Table 1.
Characteristics and treatments of the included clinical cases.
| Patient | M/F | Age (y) | Tumor type | PD-L1 expression TPS (%) |
Treatment | Radio-dose (MBq) pre-/post-treatment |
[89Zr]Zr-DFO-KN035 immunoPET/CT (h) pre-/post-treatment |
|---|---|---|---|---|---|---|---|
| 1 | M | 59 | Lung cancer with lymph node, bone and brain metastasis | 40 | Pemetrexed, Carboplatin, Sintilimab | pre-, 59.20; post-, 73.26 |
pre-, 20, 56, 115; post-, 55, 120 |
| 2 | M | 70 | Lung cancer with multiple bone metastasis | 40 | Paclitaxel, Carboplatin | pre-, 75.85 | pre-, 54, 100 |
| 3 | M | 51 | Lung cancer with bone metastasis | 60 | Excision, Paclitaxel, Carboplatin, Sintilimab | pre-, 86.21; post-, 86.58 |
pre-, 54, 120; post-, 51, 118 |
| 4 | M | 58 | Malignant lymphoma | 30 | Cyclophosphamide, Doxorubicin, Vincristine, Etoposide | pre-, 84.36; post-, 87.69 |
pre-, 53, 119; post-, 53, 124 |
| 5 | M | 54 | Lung cancer with metastasis | 20 | Pemetrexed, Carboplatin | pre-, 82.51 | pre-, 51, 123 |
| 6 | M | 77 | Lung cancer with lymph node metastasis | 70 | Pemetrexed, Sintilimab | pre-, 75.85 | pre-, 56, 124 |
| 7 | F | 37 | Nasopharyngeal carcinoma | 40 | Docetaxel, Nedaplatin | pre-, 88.43 | pre-, 53, 124 |
| 8 | F | 53 | Colorectal cancer with lymph node metastasis | 15 | Anlotinib, Penpulimab | pre-, 83.99 | pre-, 52, 124 |
| 9 | M | 58 | Nasopharyngeal carcinoma with lymph node metastasis | 60 | Docetaxel, Nedaplatin, Nimotuzumab | pre-, 81.03 | pre-, 56, 120 |
| 10 | F | 63 | Malignant melanoma of right lung, Secondary malignant tumor of cervical lymph node | 70 | Toripalimab | pre-, 77.33 | pre-, 56, 123 |
| 11 | F | 56 | Colorectal cancer with liver metastasis | <1 | Anlotinib, Sintilimab | pre-, 86.95 | pre-, 54, 120 |